CERC News and Press, Cerecor Inc. From 03/24/21

Innovation, R&D and an aging population are long-term secular trends that will provide a tailwind to the biotechnology sector. The Insurgent AI Deep Innovation Model uses Deep Learning and secular tailwinds to generate alpha. Evaluating investment strategies is challenging, es...

The following slide deck was published by Cerecor Inc. in conjunction with this event. For further details see: Cerecor (CERC) Presents At Oppenheimer 31st Annual Healthcare Conference - Slideshow

Cerecor (CERC): FY GAAP EPS of -$0.86 misses by $0.02.Revenue of $6.7M (-0.7% Y/Y) beats by $0.5M.Shares -2% AH.Press Release For further details see: Cerecor EPS misses by $0.02, beats on revenue

ROCKVILLE, Md. and CHESTERBROOK, Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced recent business progress and year-e...

NanoViricides (NNVC) +112% on effectiveness of COVID-19 drug candidates in cell culture studies.Communications Systems (JCS) +38% after entering merger agreement with Pineapple Energy.STRATA Skin Sciences (SSKN) +30% on announcing CEO Transition.CHF Solutions (CHFS) +25%.AgeX T...

Cerecor Inc. (CERC) has climbed ~11.3% in the pre-market after announcing final efficacy data from a Phase 2 trial for the monoclonal antibody, CERC-002 in patients hospitalized with COVID-19 associated pneumonia and mild to moderate acute respiratory distress syndrome (AR...

Final analysis inclusive of the 60-day safety update in the randomized placebo-controlled study demonstrated CERC-002 was statistically significant in reducing respiratory failure and mortality at Day 28 in patients hospitalized with COVID-19 associated pneumonia and mild to moderate ac...

Cerecor ([[CERC]] +9.5%) announces the appointment of Schond L. Greenway as Chief Financial Officer, effective March 1, 2021.Mr. Greenway joins Cerecor from Mesoblast Ltd., where he served as Vice President, Investor Relations. He has over 20 years’ experience in investment banking, fi...

ROCKVILLE, Md. and CHESTERBROOK, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced the appointment of Schond L. Gre...

Today, we check back in on a developmental firm called Cerecor that is focused on developing treatments for rare pediatric and orphan diseases. This is the first revisit in the last 11 months. The company seems to be advancing its pipeline and recently did a capital raise to address f...